These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25732642)

  • 1. Medical treatment of Cushing disease: new targets, new hope.
    Fleseriu M
    Endocrinol Metab Clin North Am; 2015 Mar; 44(1):51-70. PubMed ID: 25732642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pasireotide and mifepristone: new options in the medical management of Cushing's disease.
    Cohan P
    Endocr Pract; 2014 Jan; 20(1):84-93. PubMed ID: 24126229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New prospects for drug treatment in Cushing disease.
    Barahona Constanzo MJ; del Pozo Picó C
    Endocrinol Nutr; 2012 Dec; 59(10):599-605. PubMed ID: 23036936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs in the medical treatment of Cushing's syndrome--an update on mifepristone and pasireotide.
    Schteingart DE
    Expert Opin Emerg Drugs; 2012 Sep; 17(3):279-83. PubMed ID: 22533823
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances in the Medical Treatment of Cushing Disease.
    Tritos NA; Biller BMK
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):401-412. PubMed ID: 32741479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AACE/ACE Disease State Clinical Review: Medical Management of Cushing Disease.
    Hamrahian AH; Yuen KC; Hoffman AR;
    Endocr Pract; 2014 Jul; 20(7):746-57. PubMed ID: 25057099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful long-term treatment of Cushing disease with mifepristone (RU486).
    Basina M; Liu H; Hoffman AR; Feldman D
    Endocr Pract; 2012; 18(5):e114-20. PubMed ID: 22441000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osilodrostat (Isturisa) for Cushing's disease.
    Med Lett Drugs Ther; 2021 Feb; 63(1617):21-23. PubMed ID: 33647005
    [No Abstract]   [Full Text] [Related]  

  • 9. Pasireotide - Mechanism of Action and Clinical Applications.
    Sawicka-Gutaj N; Owecki M; Ruchala M
    Curr Drug Metab; 2018; 19(10):876-882. PubMed ID: 29595102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of anti-somatostatin agents on glucose metabolism.
    Vergès B
    Diabetes Metab; 2017 Oct; 43(5):411-415. PubMed ID: 28579289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of Exposure-Response Analysis in Regulatory Decision on the Selection of Starting Dose of Pasireotide for Cushing Disease.
    Yu J; Chung S; Zadezensky I; Hu K; Darstein C; Nedelman J; Mehrotra N
    J Clin Pharmacol; 2016 Aug; 56(8):1035-8. PubMed ID: 26686944
    [No Abstract]   [Full Text] [Related]  

  • 12. Medical Management of Cushing Disease.
    Tritos NA; Biller BMK
    Neurosurg Clin N Am; 2019 Oct; 30(4):499-508. PubMed ID: 31471057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly.
    Silverstein JM
    Pituitary; 2016 Oct; 19(5):536-43. PubMed ID: 27405306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats.
    Li L; Vashisht K; Boisclair J; Li W; Lin TH; Schmid HA; Kluwe W; Schoenfeld H; Hoffmann P
    Toxicol Appl Pharmacol; 2015 Aug; 286(3):224-33. PubMed ID: 25981165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pasireotide.
    Prescrire Int; 2013 Nov; 22(143):257-9. PubMed ID: 24427831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Cushing's disease: a mechanistic update.
    Cuevas-Ramos D; Fleseriu M
    J Endocrinol; 2014 Nov; 223(2):R19-39. PubMed ID: 25134660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to manage pasireotide, when using as medical treatment for Cushing's disease.
    Petersenn S
    Endocrine; 2015 Dec; 50(3):526-8. PubMed ID: 26419848
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of mifepristone in the treatment of Cushing's syndrome.
    Carroll T; Findling JW
    Drugs Today (Barc); 2012 Aug; 48(8):509-18. PubMed ID: 22916338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for Cushing's disease.
    Guelho D; Grossman AB
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):463-78. PubMed ID: 26021183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical therapy of Cushing's disease: where are we now?
    Alexandraki KI; Grossman AB
    Front Horm Res; 2010; 38():165-173. PubMed ID: 20616508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.